{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:18Z","timestamp":1787721618764,"version":"build-2784847793"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This case report explores the role of circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) monitoring in predicting tumor recurrence or metastasis after consolidative surgery in a patient with ALK-rearranged non-small cell lung cancer (NSCLC). We present a case of a 43-year-old female patient with stage IVA ALK-rearranged NSCLC who initially responded to six months of Alectinib targeted therapy, underwent consolidative surgery with postoperative pathology confirming complete response in the resected primary tumor and lymph nodes, and continued two years of maintenance therapy. During this period, three consecutive MRD tests showed negative results, leading to discontinuation of postoperative therapy. However, two months after stopping Alectinib, the patient developed new brain metastasis in the occipital lobe, necessitating re-initiation of targeted treatment. This case demonstrates the current limitations of ctDNA-based MRD monitoring in reliably predicting recurrence and determining optimal treatment duration in NSCLC. Although MRD monitoring represents an important advancement in NSCLC management, our findings emphasize the need for additional research to validate its clinical applications, particularly in guiding treatment decisions and predicting disease recurrence. The results suggest that larger prospective studies are required to establish evidence-based protocols for MRD monitoring in NSCLC patients.<\/jats:p>","DOI":"10.3389\/fonc.2026.1939564","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:47:01Z","timestamp":1787719621000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal residual disease guides postoperative therapy in a patient with ALK-rearranged adenocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinghong","family":"Xian","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Chengdu Seventh People's Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: A prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12019\/j.issn.1671-5144.2021.03.001","article-title":"\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u5206\u5b50\u6b8b\u7559\u75c5\u7076\u4e13\u5bb6\u5171\u8bc6 [Expert consensus on molecular residual disease in non-small cell lung cancer","volume":"24","year":"2021","journal-title":"\u4e2d\u56fd\u80ba\u764c\u6742\u5fd7"},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: Current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC \u2014 challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1779","article-title":"Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: A nonrandomized controlled trial","volume":"10","author":"Dong","year":"2024","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01929","article-title":"Circulating tumor DNA minimal residual disease detection of non\u2013small-cell lung cancer treated with curative intent","volume":"40","author":"Pellini","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"Of7","DOI":"10.1158\/2159-8290.Cd-nd2020-010","article-title":"MRD may predict relapse in NSCLC","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.011","article-title":"Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC","volume":"16","author":"Lam","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0572","article-title":"Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer","volume":"24","author":"Wen","year":"2019","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:47:14Z","timestamp":1787719634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1939564"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1939564","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1939564"}}